Open AccessMuscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome
Author(s) -
Nikolaus Buchmann,
Jens Fielitz,
Dominik Spira,
Maximilian König,
Kristiorman,
Graham Pawelec,
David Goldeck,
Ilja Demuth,
Elisabeth SteinhagenThiessen
Publication year - 2022
Publication title -
gerontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.397
H-Index - 94
eISSN - 1423-0003
pISSN - 0304-324X
DOI - 10.1159/000520096
Subject(s) - sarcopenia , medicine , metabolic syndrome , inflammation , lean body mass , confounding , population , odds ratio , national health and nutrition examination survey , body mass index , endocrinology , c reactive protein , gerontology , obesity , environmental health , body weight
Background: Inflammatory processes are a cause of accelerated loss of muscle mass. Metabolic syndrome (MetS) is a highly prevalent age-related condition, which may promote and be promoted by inflammation. However, whether inflammation in MetS (metaflammation) is associated with lower muscle mass is still unclear. Methods: Complete cross-sectional data on body composition, MetS, and the inflammatory markers interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor (TNF), and C-reactive protein (CRP) were available for 1,377 BASE-II participants (51.1% women; 68 ± 4 years old). Appendicular lean mass (ALM) was assessed by dual-energy X-ray absorptiometry. Low muscle mass (low ALM-to-BMI ratio [ALMBMI]) was defined according to the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. Regression models, adjusted for an increasing number of confounders (sex, age, physical activity, morbidities, diabetes mellitus type II, TSH, albumin, HbA1c, smoking habits, alcohol intake, education, and energy intake/day), were used to calculate the association between low ALMBMI and high inflammation (tertile 3) according to MetS. Results: MetS was present in 36.2% of the study population, and 9% had low ALMBMI. In the whole study population, high CRP (odds ratio [OR]: 2.7 [95% CI: 1.6–4.7; p = 0.001]) and high IL-6 (OR: 2.1 [95% CI: 1.2–1.9; p = 0.005]) were associated with low ALMBMI. In contrast, no significant association was found between TNF, IL-10, or IL-1β with low ALMBMI. When participants were stratified by MetS, results for IL-6 remained significant only in participants with MetS. Conclusions: Among BASE-II participants, low ALMBMI was associated with inflammation. Low-grade inflammation triggered by disease state, especially in the context of MetS, might favor loss of muscle mass, so a better control of MetS might help to prevent sarcopenia. Intervention studies to test whether strategies to prevent MetS might also prevent loss of muscle mass seem to be promising.